Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis. Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH J Clin Endocrinol Metab. 2013 Oct 29. PMID: 24170099. Abstract CommentRecommendBookmarkWatch